When buying syringes, bandages, and most of the things hospitals need, that’s not a big deal but the way many oncology drugs are administered these organizations end up handling all of the negotiations instead of pharmacies and insurance companies. Patients and even their healthcare providers have basically zero say in the purchasing because it’s all rolled in.
Since the US is the most profitable market in an already low margin business, the generic manufacturers can’t justify the production lines for cancer drugs without at least one of these clients so they‘re driven to extreme price wars. In good times, they eek out a profit, but in bad times when variable costs go up, they’re no longer viable.